clinical trial · NCT07529808
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
BigHat Biosciences, Inc.·phase2·not yet recruiting·n = 164
Gastric CancerGastric AdenocarcinomaGastric (Stomach) CancerGastroesophageal AdenocarcinomaGastroesophageal Cancer (GC)Gastroesophageal Junction (GEJ) AdenocarcinomaGastroesophageal Junction (GEJ) CancerGastrointestinal Cancer MetastaticBHB810
brief summary
This study is looking at how safe BHB810 is in adults with gastroesophageal adenocarcinoma (GEA) and other gastrointestinal (GI) cancers. The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.
started
Jun 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 27, 2026
official title
Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol